BPC-157 protocol · PepGuide

Standard

Weeks 1–2

5u

250 mcg · Daily

Loading. Single injection near injury site; rotate.

Weeks 3–4

7.5u

375 mcg · Daily

Step-up. Half-unit increment optional, many go directly to 10u / 500 mcg.

Weeks 5–10

10u

500 mcg · Daily

Working dose. Matches Wolverine Blend BPC-157 component.

Off

2–4 weeks

Standard washout. Re-cycle if continued tissue work needed.

Phase	How often	Dose	Units	Notes
Weeks 1–2	Daily	250 mcg	5u	Loading. Single injection near injury site; rotate.
Weeks 3–4	Daily	375 mcg	7.5u	Step-up. Half-unit increment optional, many go directly to 10u / 500 mcg.
Weeks 5–10	Daily	500 mcg	10u	Working dose. Matches Wolverine Blend BPC-157 component.
Off	2–4 weeks	–	–	Standard washout. Re-cycle if continued tissue work needed.

Aggressive

10u

500 mcg ×2 · Twice daily (AM+PM)

Community-aggressive: 1 mg/day split into two daily doses for acute soft-tissue injury, severe gut flare, or post-surgical recovery. Wide therapeutic window, no toxicity reported up to 2 mg/day. Taper to daily once acute phase resolves.

Phase	How often	Dose	Units	Notes
Aggressive	Twice daily (AM+PM)	500 mcg ×2	10u	Community-aggressive: 1 mg/day split into two daily doses for acute soft-tissue injury, severe gut flare, or post-surgical recovery. Wide therapeutic window, no toxicity reported up to 2 mg/day. Taper to daily once acute phase resolves.

Aggressive twice-daily: 4–6 wks split-dose / 4 wks off.

Cycle & timing

Cycle: 8–10 wks on / 2–4 wks off (daily microdose). Aggressive twice-daily: 4–6 wks split-dose / 4 wks off.

Timing: Daily, anytime; food doesn't affect; consistency matters.

Where: SubQ near injury site. Rotate. Do NOT inject into a joint.

What to expect

Pain reduction at injury site within days. Tissue-repair progress at 3–4 weeks. Gut symptoms often improve within 1–2 weeks.

How much to buy

For 10-wk @ 500 mcg × 7/wk:

15

× 2mg vials

6

× 5mg vials

3

× 10mg vials

Men & women

Unisex healing peptide, no meaningful sex or cycle effect; same protocol for men and women. Limited data in both sexes; avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for BPC-157. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

10u

Volume

0.10 mL

Strength

5 mg/mL

Doses per vial

10

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
2 mg	0.4 mL	5 mg/mL
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

2 mg: 1 unit = 0.05 mg

Storage

PowderFreeze-dried: -4°F (years stable).
MixedReconstituted: 36–46°F, up to 8 weeks with verified product + continuous cold chain.
Toss itDiscard if cloudy, discoloured, or particulates.

Don't use if: Active malignancy · Pregnancy · Lactation

Stop if you notice

New mass or unexpected tissue growth at any injection site
Persistent injection-site reactions >7 days
New unexplained GI symptoms

Side effects

Usually minimal. Occasional lightheadedness or injection-site irritation.

Drug interactions

NSAIDs (ibuprofen, Advil, Aleve, aspirin): they don't cancel out BPC-157; that's a myth; BPC-157 works by a different route, and in animals it even protects the gut/liver from NSAID damage. Still skip NSAIDs during a repair cycle, because NSAIDs slow tissue healing on their own; use Tylenol (acetaminophen) for pain instead. Anticoagulants (warfarin, DOACs): preclinical hints at coagulation effects; monitor INR/anti-Xa if combining.

Labs

hsCRP (baseline + end)

What these labs mean →

Warnings

Human data = small pilots (MSK pain, interstitial cystitis, IV) + Phase II UC; none for SubQ injury dosing. FDA Category 2 (2023), bulk-compounding restricted. PCAC RECOMMENDED it for the 503A bulks list, 8–6 (Jul 2026; advisory, non-binding; FDA rulemaking pending).

Patient education

Research compound, FDA Category 2 (2023); request a COA per lot. All use off-label. Local injection near target tissue for orthopedic use; SubQ near abdomen for systemic gut/inflammatory use. Stop for new lump, injection-site reaction >7 days, or GI bleeding. Do not use during active cancer or pregnancy/lactation, angiogenic and growth-promoting.

These apply on top of the universal safety rules.

Pairs well with

TB-500

Wolverine stack

TB-500 (Thymosin Beta-4)

Ipamorelin / CJC No DAC

GH support

Ipamorelin CJC-1295 (No DAC)

GHK-Cu

skin/wound healing

GHK-Cu

Tesamorelin

GHRH support

Tesamorelin

Avoid with

NSAIDs during a repair cycle

ibuprofen/Advil/Aleve slow healing on their own; use Tylenol for pain

High-dose vitamin C same session

oxidation

Active malignancy

GLOW / KLOW Blend

already contains BPC-157

GLOW Blend KLOW Blend

Can BPC-157 + TB-500 (Thymosin Beta-4) share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

Changes from the guide

The guide contradicted itself or had a slip here, so this page differs from the PDF:

Patient education also gave a different cycle (Cycle 4–6 wks on / 2–4 wks off). Removed so the page uses the main cycle line: 8–10 wks on / 2–4 wks off (daily microdose). Aggressive twice-daily: 4–6 wks split-dose / 4 wks off.

What it does

Community off-label use.

Stimulates angiogenesis via VEGF, activates GH receptor on tendon fibroblasts, promotes nitric-oxide signalling, suppresses NF-κB.

References

researchdosing peptidedosages PubMed thepeptidereport peptides.id

From the guide, page 22.